Omeprazol Tartet Ciclum Farma Unipessoal (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Tartet Ciclum Farma Unipessoal, is a proton pump inhibitor presented as a tablet for oral use. It reduces stomach acid production and is used to treat acid‑related gastrointestinal conditions in adults and children. GNH USA supplies Omeprazol Tartet Ciclum Farma Unipessoal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazol Tartet Ciclum Farma Unipessoal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole acts on the gastric proton pump to manage acid‑related disorders.

- Gastro‑esophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal erosion. - Peptic ulcer disease: supports ulcer healing by maintaining a less acidic gastric environment. - Zollinger‑Ellison syndrome: controls excessive gastric acid secretion associated with the condition. - Helicobacter pylori eradication regimens: used as adjunct therapy to improve eradication rates when combined with antibiotics. - NSAID‑induced gastropathy: helps prevent ulcer formation in patients requiring long‑term NSAID therapy.

Adverse reactions to omeprazole are generally mild and dose‑dependent.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: watery stools, often transient. - Nausea: occasional feeling of stomach upset. - Abdominal pain: cramping or discomfort. - Flatulence: increased gas production. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Acute interstitial nephritis: renal inflammation with possible decreased urine output. - Hypomagnesemia: low serum magnesium causing muscle cramps or arrhythmias. - Stevens‑Johnson syndrome: severe skin and mucosal reactions. - Liver enzyme elevation: increased ALT/AST indicating hepatic stress. - Bone fracture risk: potential reduction in calcium absorption with long‑term use.

When prescribing omeprazole, clinicians should consider several safety aspects.

- Assess renal function: adjust use in severe renal impairment. - Evaluate hepatic status: use with caution in moderate to severe liver disease. - Review concomitant medications: potential for drug‑drug interactions. - Monitor long‑term therapy: consider periodic assessment of magnesium and vitamin B12 levels. - Pregnancy and lactation: weigh benefits against potential risks. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Omeprazole may alter the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atazanavir: decreased absorption, loss of antiviral efficacy. - Methotrexate (high dose): increased serum concentrations, risk of toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, monitor coagulation parameters. - Digoxin: possible rise in serum levels, observe for toxicity signs. - Diazepam: enhanced sedation, adjust dose if needed. - Ketoconazole: reduced absorption, consider alternative antifungal. - Iron salts: decreased iron uptake, separate administration times.